Fulgent Genetics Inc. (FLGT)
Fulgent Genetics Statistics
Share Statistics
Fulgent Genetics has 30.87M shares outstanding. The number of shares has increased by 3.15% in one year.
Shares Outstanding | 30.87M |
Shares Change (YoY) | 3.15% |
Shares Change (QoQ) | 0.91% |
Owned by Institutions (%) | 56.01% |
Shares Floating | 19.88M |
Failed to Deliver (FTD) Shares | 8.46K |
FTD / Avg. Volume | 1.86% |
Short Selling Information
The latest short interest is 1.52M, so 4.92% of the outstanding shares have been sold short.
Short Interest | 1.52M |
Short % of Shares Out | 4.92% |
Short % of Float | 8.96% |
Short Ratio (days to cover) | 1.87 |
Valuation Ratios
The PE ratio is -13.08 and the forward PE ratio is -29.33. Fulgent Genetics's PEG ratio is 0.17.
PE Ratio | -13.08 |
Forward PE | -29.33 |
PS Ratio | 1.97 |
Forward PS | 1.6 |
PB Ratio | 0.49 |
P/FCF Ratio | -29 |
PEG Ratio | 0.17 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Fulgent Genetics.
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.85, with a Debt / Equity ratio of 0.
Current Ratio | 4.85 |
Quick Ratio | 4.85 |
Debt / Equity | 0 |
Debt / EBITDA | -0.01 |
Debt / FCF | -0.02 |
Interest Coverage | -434.81 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity | n/a |
Return on Assets | n/a |
Return on Invested Capital | n/a |
Revenue Per Employee | $215.89K |
Profits Per Employee | $-32.53K |
Employee Count | 1,313 |
Asset Turnover | 0.23 |
Inventory Turnover | n/a |
Taxes
Income Tax | -8.14M |
Effective Tax Rate | 15.66% |
Stock Price Statistics
The stock price has increased by -8.78% in the last 52 weeks. The beta is 1.37, so Fulgent Genetics's price volatility has been higher than the market average.
Beta | 1.37 |
52-Week Price Change | -8.78% |
50-Day Moving Average | 17.15 |
200-Day Moving Average | 19.55 |
Relative Strength Index (RSI) | 61.53 |
Average Volume (20 Days) | 454.17K |
Income Statement
In the last 12 months, Fulgent Genetics had revenue of 283.47M and earned -42.71M in profits. Earnings per share was -1.41.
Revenue | 283.47M |
Gross Profit | 107.22M |
Operating Income | -73.92M |
Net Income | -42.71M |
EBITDA | -73.92M |
EBIT | -73.92M |
Earnings Per Share (EPS) | -1.41 |
Balance Sheet
The company has 55.14M in cash and 412K in debt, giving a net cash position of 54.73M.
Cash & Cash Equivalents | 55.14M |
Total Debt | 412K |
Net Cash | 54.73M |
Retained Earnings | 590.47M |
Total Assets | 1.22B |
Working Capital | 280.67M |
Cash Flow
In the last 12 months, operating cash flow was 21.06M and capital expenditures -40.31M, giving a free cash flow of -19.25M.
Operating Cash Flow | 21.06M |
Capital Expenditures | -40.31M |
Free Cash Flow | -19.25M |
FCF Per Share | -0.64 |
Margins
Gross margin is 37.82%, with operating and profit margins of -26.08% and -15.07%.
Gross Margin | 37.82% |
Operating Margin | -26.08% |
Pretax Margin | -18.33% |
Profit Margin | -15.07% |
EBITDA Margin | -26.08% |
EBIT Margin | -26.08% |
FCF Margin | -6.79% |
Dividends & Yields
FLGT does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Payout Ratio | n/a |
Earnings Yield | n/a |
FCF Yield | n/a |
Analyst Forecast
The average price target for FLGT is $16, which is -15.4% lower than the current price. The consensus rating is "Hold".
Price Target | $16 |
Price Target Difference | -15.4% |
Analyst Consensus | Hold |
Analyst Count | 1 |
Scores
Altman Z-Score | 4.76 |
Piotroski F-Score | 5 |